PIK 75

Known as: PIK-75 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2017
012320072017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
We describe the potential benefit of PIK-75 in combination of gemcitabine to treat pancreatic cancer in a preclinical mouse model… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Class IA phosphatidyl inositol-3 kinases (PI3-K) are important targets in cancer therapy and are essential to immune responses… (More)
Is this relevant?
2014
2014
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing… (More)
Is this relevant?
2013
2013
PIK-75 is a phosphatidylinositol 3-kinase (PI3K) inhibitor that shows selectivity toward p110-α over the other PI3K class Ia… (More)
Is this relevant?
2012
2012
Many malignancies show increased expression of the epidermal growth factor (EGF) receptor family member ErbB3 (HER3). ErbB3 binds… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
The combination of molecular modeling and X-ray crystallography has failed to yield a consensus model of the mechanism for… (More)
  • table 1
Is this relevant?
2010
2010
A promising therapeutic approach to diminish pathological inflammation is to inhibit the increased production and/or biological… (More)
Is this relevant?
2008
2008
FOXO proteins are direct targets of PI3K/Akt signaling and they integrate the signals of several other transduction pathways at… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Recent genetic knock-in and pharmacological approaches have suggested that, of class IA PI3Ks (phosphatidylinositol 3-kinases… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2007
2007
Platelets release insulin-like growth factor-1 (IGF-1) from alpha granules upon activation. We have investigated the regulation… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?